Document is current

Any future updates will be listed below

Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities

Crossref DOI link: https://doi.org/10.1007/s42000-019-00145-1

Published Online: 2019-11-13

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark